BPBo Peng

Bo Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bo Peng has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Fan Feng

    MOE Key Laboratory of Protein Sciences, State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Medicine, Tsinghua University, Beijing 100084, China

    1 shared publication
  • Fan Zhao

    MOE Key Laboratory of Protein Sciences, State Key Laboratory of Molecular Oncology, Beijing Frontier Research Center for Biological Structure, School of Medicine, Tsinghua University, Beijing 100084, China

    1 shared publication
  • Fen Yang

    Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, Jiangsu, PR China

    1 shared publication
  • Haitao Li

    Tsinghua University

    1 shared publication
  • Juntao Gao

    Tsinghua University

    1 shared publication
  • Ke Yao

    School of Pharmaceutical Sciences, Tsinghua University, Beijing, China

    1 shared publication

Latest Publications

  • Molecular Basis for SPINDOC-Spindlin1 Engagement and Its Role in Transcriptional Attenuation

    by Fan Zhao, Yafang Deng, Fen Yang, Yan Yan, Fan Feng, Bo Peng, Juntao Gao, Mark T. Bedford, Haitao Li


  • Open Access

    Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma

    by Meng Nie, Ke Yao, Xinsheng Zhu, Na Chen, Nan Xiao, Yi Wang, Bo Peng, LiAng Yao, Peng Li, Peng Zhang, et al.

    Metabolic reprogramming evolves during cancer initiation and progression. However, thorough understanding of metabolic evolution from preneoplasia to lung adenocarcinoma (LUAD) is still limited. Here, we perform large-scale targeted metabolomics on resected lesions and plasma obtained from invasive LUAD and its precursors, and decipher the metabolic trajectories from atypical adenomatous hyperplasia (AAH) to adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IAC), revealing that perturbed metabolic pathways emerge early in premalignant lesions. Furthermore, three panels of plasma metabolites are identified as non-invasive predictive biomarkers to distinguish IAC and its precursors with benign diseases. Strikingly, metabolomics clustering defines three metabolic subtypes of IAC patients with distinct clinical characteristics. We identify correlation between aberrant bile acid metabolism in subtype III with poor clinical features and demonstrate dysregulated bile acid metabolism promotes migration of LUAD, which could be exploited as potential targetable vulnerability and for stratifying patients. Collectively, the comprehensive landscape of the metabolic evolution along the development of LUAD will improve early detection and provide impactful therapeutic strategies.